Standout Papers
- CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL (2003)
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2008)
Immediate Impact
1 by Nobel laureates 7 from Science/Nature 146 standout
Citing Papers
Blinded, randomized trial of sonographer versus AI cardiac function assessment
2023 StandoutNature
Heart Failure With Reduced Ejection Fraction
2020 Standout
Works of C. B. Granger being referenced
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
2003 Standout
Clinical Features and Contemporary Management of Patients with Low and Preserved Ejection Fraction Heart Failure: Baseline Characteristics of Patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Programme
2003
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| C. B. Granger | 3279 | 571 | 530 | 686 | 41 | 3.8k | |
| Ali Oto | 2715 | 729 | 196 | 538 | 86 | 3.6k | |
| Cécile Laroche | 4145 | 544 | 333 | 392 | 92 | 4.9k | |
| Christian Selmer | 1740 | 430 | 353 | 980 | 53 | 3.5k | |
| George J. Philippides | 2885 | 1058 | 317 | 383 | 21 | 3.8k | |
| Jan Heeringa | 4237 | 995 | 401 | 575 | 47 | 6.2k | |
| Paul Chang | 3179 | 203 | 580 | 375 | 36 | 3.6k | |
| Tina Ken Schramm | 1472 | 507 | 246 | 596 | 24 | 2.7k | |
| Jean‐Pierre Boissel | 1639 | 500 | 379 | 446 | 47 | 2.8k | |
| Jayashri Aragam | 2063 | 346 | 313 | 235 | 57 | 2.7k | |
| Connie N. Hess | 1419 | 1538 | 412 | 510 | 88 | 3.0k |
All Works
Loading papers...